Showing 2481-2490 of 18620 results for "".
Nutrition and Acne: Evidence-Based Insights for Smarter Dietary Guidance
https://reachmd.com/programs/clinicians-roundtable/nutrition-acne-evidence-based-guidance/49090/Many patients turn to dietary changes before ever filling a prescription for acne. But which interventions actually make a difference? To find out, Dr. John Barbieri breaks down the evidence behind nutrition’s role in acne. From low-glycemic diets and vitamin D to omega-3s and zinc, he highlights prAddressing Itch in Prurigo Nodularis Clinical Trials
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37170/Raja Sivamani, MD, MS, AP, an integrative dermatologist and Adjunct Associate Professor of Clinical Dermatology at the University of California, Davis, addresses how future prurigo nodularis trials could better address the heterogeneity in disease burden and patient-reported outcomes.Evaluating Structured Interventions for Cognitive Support in MS
https://reachmd.com/programs/Audioabstracts/structured-interventions-cognitive-support-ms/54242/For patients with multiple sclerosis (MS), cognitive impairment can quietly erode independence and quality of life. In this AudioAbstract, Dr. Hallie Blevins discusses a head-to-head comparison of cognitive training, aerobic exercise, and a combined approach and explores how we can better support coEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/54612/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urSurgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
https://reachmd.com/programs/clinicians-roundtable/surgery-gastroesophageal-cancer-surveillance-intervention/49171/For patients with locally advanced gastroesophageal cancer, surgery remains a critical component of curative treatment—even in the era of chemoradiation and advanced imaging. Dr. Daniela Molena explores the challenges of assessing complete clinical response and the risks of non-operative managemInnovation in Androgenetic Alopecia
https://practicaldermatology.com/series/c-suite-chats/innovation-in-androgenetic-alopecia/54265/Diana Harbort, President of Cosmo Pharmaceuticals' Dermatology Division, discusses the need for new innovations in androgenetic alopecia and the promise of clascoterone for treating the condition.Expert Opinions on Characteristics of Patients With IgA Nephropathy (IgAN) at High Risk of Progression
https://reachmd.com/programs/medical-industry-feature/igan-high-risk-progression-characteristics/39256/In patients with IgA nephropathy (IgAN), pathological findings can help provide important prognostic information beyond clinical context. Drs Dana Rizk, Sanjeev Sethi, Leal C. Herlitz, and Carla Nester provide expert insights on integrating these findings with clinical and demographic data to assessUnderstanding the Growing Impacts of Obesity on Patient Outcomes and Care Delivery
https://reachmd.com/programs/clinicians-roundtable/understanding-the-growing-impacts-of-obesity-patient-outcomes-and-care-delivery/39652/With obesity rates rising to unprecedented levels, clinicians face critical challenges in managing associated complications. Hear from Dr. Sujith Cherian as he explores obesity’s systemic impact, from cardiovascular and infectious risks to medication dosing and hospital care complexities. Dr.Identifying and Managing Violence Risk in Schizophrenia Care
https://reachmd.com/programs/frontlines-schizophrenia/violence-risk-schizophrenia-care/49152/What factors increase the risk of violence in patients with schizophrenia, and how can clinicians respond effectively? To find out, Dr. Alexandria May speaks with Dr. Ragy Girgis to examine evidence-based approaches for assessing and managing violence risk. They discuss the role of substance use, meDermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research valida